Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 59 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus

Dharmalingam Mala, Sriram Usha, Baruah Manash P

Year : 2011| Volume: 15| Issue : 1 | Page no: 9-17

   This article has been cited by
1 Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists
Luis Peña Icart,Fernando Gomes Souza Jr,Luís Maurício T. R. Lima
Journal of Microencapsulation. 2021; : 1
[Pubmed]  [Google Scholar] [DOI]
2 Liraglutide treatment and acylcarnitine profiles in Egyptian obese insulin-resistant females
Neveen A. Hussein,Samia A. Ebied,Hoda A. Nour,Usama K. Zaki,Sahar M. EL-Kotishy,Tarek M. Salem
European Journal of Pharmacology. 2020; : 173668
[Pubmed]  [Google Scholar] [DOI]
3 Pre-Clinical Evaluation of a Modified Cyclodextrin-Based Nanoparticle for Intestinal Delivery of Liraglutide
Elena Presas,Sulay Tovar,Juan Cuñarro,Joseph P. OæShea,Caitriona M. OæDriscoll
Journal of Pharmaceutical Sciences. 2020;
[Pubmed]  [Google Scholar] [DOI]
4 Mechanistic insights into the pH-dependent membrane peptide ATRAM
Vanessa P. Nguyen,Loganathan Palanikumar,Stephen J. Kennel,Daiane S. Alves,Yujie Ye,Jonathan S. Wall,Mazin Magzoub,Francisco N. Barrera
Journal of Controlled Release. 2019; 298: 142
[Pubmed]  [Google Scholar] [DOI]
5 Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Seungah Lee,Dong Yun Lee
Annals of Pediatric Endocrinology & Metabolism. 2017; 22(1): 15
[Pubmed]  [Google Scholar] [DOI]
6 Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials
Fang Zhang,Lizhi Tang,Yuwei Zhang,Qingguo Lü,Nanwei Tong
Scientific Reports. 2017; 7(1)
[Pubmed]  [Google Scholar] [DOI]
7 Laminarin counteracts diet-induced obesity associated with glucagon-like peptide-1 secretion
Liusong Yang,Lina Wang,Canjun Zhu,Junguo Wu,Yexian Yuan,Lulu Yu,Yaqiong Xu,Jingren Xu,Tao Wang,Zhengrui Liao,Songbo Wang,Xiaotong Zhu,Ping Gao,Yongliang Zhang,Xiuqi Wang,Qingyan Jiang,Gang Shu
Oncotarget. 2017; 8(59): 99470
[Pubmed]  [Google Scholar] [DOI]
8 Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis
Carrie McAdam-Marx,Hiep Nguyen,Marisa B. Schauerhamer,Mukul Singhal,Sudhir Unni,Xiangyang Ye,David Cobden
Clinical Therapeutics. 2016; 38(12): 2642
[Pubmed]  [Google Scholar] [DOI]
9 Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes
C. d. Graaf,D. Donnelly,D. Wootten,J. Lau,P. M. Sexton,L. J. Miller,J.-M. Ahn,J. Liao,M. M. Fletcher,D. Yang,A. J. H. Brown,C. Zhou,J. Deng,M.-W. Wang
Pharmacological Reviews. 2016; 68(4): 954
[Pubmed]  [Google Scholar] [DOI]
10 Novel Exenatide Analogs with Peptidic Albumin Binding Domains: Potent Anti-Diabetic Agents with Extended Duration of Action
Odile E. Levy,Carolyn M. Jodka,Shijun Steven Ren,Lala Mamedova,Abhinandini Sharma,Manoj Samant,Lawrence J. D’Souza,Christopher J. Soares,Diane R. Yuskin,Li Jenny Jin,David G. Parkes,Krystyna Tatarkiewicz,Soumitra S. Ghosh,Nigel Irwin
PLoS ONE. 2014; 9(2): e87704
[Pubmed]  [Google Scholar] [DOI]


Read this article